@article{bacaf425b4b4449d8a32b9097e46eebc,
title = "Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial",
abstract = "Carboplatin/paclitaxel is the standard first-line chemotherapy for patients with advanced ovarian cancer. Multicentre Italian Trials in Ovarian Cancer-2 (MITO-2), an academic multicenter phase III trial, tested whether carboplatin/pegylated liposomal doxorubicin (PLD) was more effective than standard chemotherapy.",
keywords = "Adult, Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Disease-Free Survival, Doxorubicin, Female, Humans, Middle Aged, Ovarian Neoplasms, Polyethylene Glycols, Quality of Life, Adult, Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Disease-Free Survival, Doxorubicin, Female, Humans, Middle Aged, Ovarian Neoplasms, Polyethylene Glycols, Quality of Life",
author = "S Pignata and Giovanni Scambia and Ferrandina, {Maria Gabriella} and A Savarese and R Sorio and E Breda and V Gebbia and Patrizia Musso and L Frigerio and Av Lombardi and A Febbraro and {Del Medico}, P and A Ferro and P Scollo and S Tamberi and A Brandes and A Ravaioli and Valerio and E Aitini and Davide Natale and L Scaltriti and Stefano Greggi and C Pisano and Domenica Lorusso and Vanda Salutari and Francesco Legge and {Di Maio}, M and Antonio Morabito and C Gallo and Francesca Perrone",
year = "2011",
doi = "10.1200/JCO.2010.33.8566",
language = "English",
volume = "29",
pages = "3628--3635",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "-American Society of Clinical Oncology. , 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, USA, VA, 22314preceden",
}
